Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common form of feline cardiomyopathy and the leading cardiac disease in adult domestic cats, characterized by pathological thickening (hypertrophy) of the left ventricular myocardium in the absence of a systemic cause such as hypertension or hyperthyroidism [1][2]. It may affect up to approximately 15% of the domestic cat population, though the vast majority of affected cats harbor subclinical (preclinical) disease and show no overt clinical signs [2][8]. HCM results in impaired diastolic filling and, in severe cases, dynamic left ventricular outflow tract obstruction, left atrial enlargement, congestive heart failure (CHF), arterial thromboembolism (ATE), or sudden death [1][2]. The etiology is largely unknown in most cats, although genetic mutations in sarcomeric proteins have been identified in certain breeds [2].

Genetic and Molecular Basis

The etiology of feline HCM is heterogeneous and largely idiopathic. In Maine Coon and Ragdoll cats, specific point mutations in the cardiac myosin-binding protein C gene (MYBPC3) have been identified as autosomal dominant traits, but these mutations account for only a fraction of all HCM cases and are not found in most other breeds or in domestic shorthair cats [2]. The broader genetic and molecular underpinnings in the majority of cats remain poorly characterized [1][2].

Pathophysiology

The hallmark lesion is concentric left ventricular hypertrophy (LVH)—diffuse or segmental thickening of the left ventricular walls and/or interventricular septum—caused by an increase in cardiomyocyte size (hypertrophy) and interstitial fibrosis [2]. At the cellular level, abnormal sarcomeric protein function leads to increased energy consumption, impaired calcium handling, and myocardial disarray. The downstream consequences include:

• ·Diastolic dysfunction: The hypertrophied, stiffened left ventricle relaxes poorly and fills at elevated pressures; this is the central functional abnormality in HCM even when systolic function remains preserved [1][2]
• ·Dynamic left ventricular outflow tract obstruction (LVOTO): Occurs in a subset of cats due to systolic anterior motion (SAM) of the mitral valve leaflet, generating a pressure gradient that further stresses the myocardium [2]
• ·Left atrial (LA) enlargement: Chronically elevated left ventricular filling pressures cause LA dilation, which is a major risk factor for CHF and ATE [1][6]
• ·Congestive heart failure: When LA pressures rise sufficiently, pulmonary venous congestion leads to pulmonary edema and/or pleural effusion [1][2]
• ·Arterial thromboembolism: LA enlargement promotes blood stasis, endothelial dysfunction, and a hypercoagulable state, resulting in thrombus formation (most commonly in the left auricle) and subsequent embolization to the aortic trifurcation ("saddle thrombus") or other sites [1][2]
• ·Myocardial ischemia: Small-vessel coronary disease and elevated diastolic wall stress reduce subendocardial perfusion, contributing to fibrosis and arrhythmias [2]

Breed and Demographic Risk Factors

Domestic shorthair cats and male cats are reported to be over-represented clinically [2]. Purebreds including Maine Coon, Ragdoll, British Shorthair, Norwegian Forest Cat, and Persian are recognized higher-risk breeds [2]. Disease can manifest from 3 months of age onward, with a wide age range at diagnosis [2][8].

Transient Myocardial Thickening

A subset of cats with apparent HCM and CHF demonstrate resolution of LV wall thickening (transient myocardial thickening, TMT), suggesting that in some cases reversible metabolic or inflammatory processes may mimic true HCM; these cases underscore the importance of identifying and treating potential secondary causes [7].

Diagnosis of HCM requires echocardiographic confirmation of LV hypertrophy after exclusion of secondary causes (hypertension, hyperthyroidism) [1][2].

Physical Examination

• ·Auscultation for heart murmurs, gallop sounds, arrhythmias, and lung crackles
• ·Assessment of respiratory rate and effort; increased resting respiratory rate (>40 breaths/min at home) is an important early warning sign [1]
• ·Femoral pulse quality assessment (weak or absent in ATE) [2]

Echocardiography (Gold Standard)

• ·Definitive diagnosis requires demonstration of increased diastolic left ventricular wall thickness (interventricular septum or LV free wall ≥6 mm in diastole in a non-hyperdynamic heart) after ruling out secondary causes [1][2]
• ·Two-dimensional and M-mode measurements of wall thickness, LV chamber dimensions, and LA size
• ·LA-to-aortic root ratio (LA:Ao ≥1.5–1.6 is clinically significant; larger ratios associated with worse prognosis) [1][6]
• ·Doppler assessment of mitral inflow, pulmonary vein flow, and tissue Doppler imaging for diastolic dysfunction grading [1][2]
• ·Detection of SAM, LVOTO, and dynamic pressure gradients [2]
• ·Identification of spontaneous echocardiographic contrast ("smoke") or thrombus in the LA [1]

Thoracic Radiography

• ·Assess for cardiomegaly, pulmonary edema (perihilar or diffuse interstitial-to-alveolar pattern), and pleural effusion [1][4]
• ·The classic "valentine heart" shape due to LA and LA appendage enlargement may be visible on dorsoventral projection

Electrocardiography (ECG)

• ·May reveal left ventricular enlargement patterns, conduction disturbances, supraventricular or ventricular arrhythmias [2]
• ·Normal ECG does not exclude HCM

Biomarkers

• ·NT-proBNP (N-terminal pro–B-type natriuretic peptide): Elevated in cats with significant structural heart disease; useful for screening and monitoring; a high NT-proBNP in a dyspneic cat supports cardiac over respiratory cause [1][2]
• ·Cardiac troponin I (cTnI): Elevated with myocardial injury; correlates with disease severity; high troponin associated with poorer prognosis [1][2]
• ·Point-of-care NT-proBNP can guide emergency triage of dyspneic cats

Laboratory and Blood Tests

• ·Complete blood count (CBC): Generally unremarkable in uncomplicated HCM; anemia (low HCT) may worsen cardiac output; thrombocytopenia (low PLT) may occur post-ATE due to thrombus consumption
• ·Serum biochemistry: Mandatory to exclude secondary causes:
  • ·BUN and CREA (creatinine): Elevated in cats with poor cardiac output or post-ATE renal hypoperfusion; azotemia is common in cats with CHF and ATE and complicates diuretic therapy
  • ·ALT: May be mildly elevated if hepatic congestion is present
  • ·Albumin (ALB): Low albumin may indicate poor nutritional status or chronic disease; hypoalbuminemia can lower colloid osmotic pressure and worsen effusions
  • ·Total bilirubin (TBIL): May be elevated with hepatic congestion or hemolysis post-ATE
  • ·Potassium: Hypokalemia is a risk with furosemide therapy and must be monitored
  • ·Phosphorus, electrolytes: Monitored during CHF management
• ·Thyroid function (total T4): Must be measured in cats ≥6 years to exclude hyperthyroidism as a cause of secondary LVH [1][2]
• ·Blood pressure (systolic): Mandatory to exclude hypertension-induced LVH (systolic BP >160–180 mmHg) [1][2]

Genetic Testing

• ·Available for MYBPC3 mutations (A31P in Maine Coon, R820W in Ragdoll); positive result confirms genetic risk but negative result does not exclude HCM [2]
• ·Not a substitute for echocardiographic screening, especially in breeding programs

There is currently no curative treatment for HCM, and no therapy has been conclusively proven to slow disease progression in subclinical cats, though research is ongoing [1][2][3]. Management is therefore primarily directed at controlling clinical signs, preventing complications, and improving quality of life.

Subclinical (Preclinical) HCM

• ·Cats with mild hypertrophy and no LA enlargement: No treatment is currently recommended; regular monitoring every 6–12 months with echocardiography and NT-proBNP is advised [1][2]
• ·Cats with significant LA enlargement (LA:Ao ≥1.5–1.6) but no CHF: Clopidogrel (18.75 mg/cat PO q24h) is recommended to reduce ATE risk [1][2]; some cardiologists initiate an ACE inhibitor, though evidence is limited
• ·mTOR pathway modulation (rapamycin): The RAPACAT trial showed that once-weekly delayed-release rapamycin over 6 months significantly halted the progression of LV hypertrophy in cats with subclinical, nonobstructive HCM, representing a promising disease-modifying avenue [3]; however, this is not yet standard of care
• ·Atenolol: A beta-blocker used in cats with dynamic LVOTO (SAM with significant gradient) to reduce heart rate and obstruction; may reduce clinical signs in symptomatic obstructive HCM [2]

Congestive Heart Failure (Acute)

• ·Furosemide (loop diuretic): The cornerstone of acute CHF management; administered IV or IM at 1–2 mg/kg, repeated as needed to relieve pulmonary edema or pleural effusion [1][2]
• ·Oxygen supplementation: Low-stress oxygen therapy (oxygen cage) in dyspneic cats
• ·Thoracocentesis: Immediate pleural effusion drainage if present; highly effective and life-saving [1]
• ·Minimize handling and stress: Critical; cats in respiratory distress are at high risk of acute decompensation
• ·Nitroglycerin: Topical, occasionally used for vasodilation in acute CHF; limited evidence

Congestive Heart Failure (Chronic Maintenance)

• ·Oral furosemide: 1–2 mg/kg PO q12–24h; dose titrated to the lowest effective level while monitoring renal function and electrolytes [1][2]
• ·ACE inhibitors (e.g., enalapril, benazepril): Commonly used; theoretical benefit in reducing afterload and neurohormonal activation; may help preserve renal function [1]
• ·Spironolactone: Potassium-sparing diuretic/aldosterone antagonist; used as adjunct diuretic therapy; monitor for dermatological side effects (facial alopecia, ulcerations) in cats [1]
• ·Atenolol: Used in cats with heart rate–dependent diastolic filling compromise or LVOTO; target resting heart rate reduction [2]
• ·Clopidogrel: Continued for ATE prevention in all cats with LA enlargement or prior ATE [1][2]
• ·Low-dose aspirin: Occasionally combined with clopidogrel in very high-risk cats, though increased bleeding risk must be considered [1]

Arterial Thromboembolism (ATE)

• ·Prognosis is guarded to grave; immediate assessment of limb viability and overall condition is essential [1][2]
• ·Analgesia: Opioids (e.g., buprenorphine, methadone) are critical for pain management
• ·Heparin: Unfractionated or low-molecular-weight heparin to prevent clot extension
• ·Antiplatelet therapy: Clopidogrel initiated or continued
• ·Supportive care: Fluid therapy with caution (risk of worsening CHF), limb warming/protection, nutritional support
• ·Limb reperfusion injury (hyperkalemia, acidosis) and multi-organ failure are major concerns; monitoring of electrolytes, BUN, CREA, and potassium is essential
• ·Thrombolytic therapy (e.g., tissue plasminogen activator) has been used but carries significant hemorrhagic risk and mixed outcomes [2]

Monitoring

• ·Regular echocardiographic reassessment (every 3–12 months depending on severity)
• ·Serial NT-proBNP and cTnI measurements
• ·Home respiratory rate monitoring by owners (resting rate >40 breaths/min should prompt veterinary evaluation) [1]
• ·Serial renal function and electrolyte monitoring in cats on diuretics

Prognosis in HCM is highly variable and depends primarily on disease stage, presence of LA enlargement, and occurrence of complications [1][2][6].

Subclinical HCM

• ·Many cats with subclinical HCM have a normal or near-normal life expectancy; severe complications (CHF or ATE) occur in only a minority of subclinically affected cats [2]
• ·In a large screening study, the majority of cats with echocardiographic HCM had mild disease [8]

Congestive Heart Failure

• ·Survival times after first CHF episode are highly variable: median survival reported in various studies ranges from approximately 3–18 months after diagnosis of CHF [2][6]
• ·LA enlargement is one of the most robust negative prognostic indicators; cats with marked LA enlargement (LA:Ao >2.0) have significantly shorter survival times [6]
• ·Left atrial enlargement, CHF, and ATE are all independently associated with decreased survival [6]
• ·Some cats with CHF can be managed for extended periods with appropriate therapy, while others die acutely or require euthanasia shortly after diagnosis [1][2]

Arterial Thromboembolism

• ·ATE carries a grave short-term prognosis; reported in-hospital or 30-day mortality rates range from approximately 30–70% depending on the study population and severity of limb ischemia [2][6]
• ·Cats surviving the acute ATE episode remain at very high risk for recurrence; median survival after ATE ranges from weeks to approximately 6–12 months in published series [2][6]
• ·Poor prognostic indicators for ATE include hypothermia, bilateral limb involvement, CHF concurrent with ATE, and severe azotemia [2]

Echocardiographic Prognostic Variables

• ·LA size (LA:Ao ratio) is the single most important echocardiographic prognostic factor [6]
• ·Reduced fractional shortening (systolic dysfunction) is associated with shorter survival [6]
• ·Elevated cTnI and NT-proBNP are associated with more severe disease and worse outcome [1][2]

Transient Myocardial Thickening (TMT)

• ·A subset of cats (~reported in a case series of 21 cats) have resolution of LV thickening and CHF, associated with a more favorable outcome than persistent HCM; this phenotype should be considered when managing cats presenting with apparent HCM and CHF [7]

Sudden Death

• ·Sudden cardiac death can occur at any disease stage, including in cats with previously mild or subclinical disease; frequency is difficult to quantify but is a recognized complication [1][2]

There is no definitive method to prevent the development of HCM in cats, as the etiology is largely genetic or idiopathic and no modifiable environmental risk factors have been established [1][2]. However, the following measures are recommended:

Genetic Screening in Breeding Cats

• ·Genetic testing for known MYBPC3 mutations (A31P in Maine Coon; R820W in Ragdoll) is available and should be incorporated into breeding programs for these high-risk breeds [2]
• ·Cats that test homozygous positive have an earlier onset and more severe disease; removing mutation-positive cats from breeding programs can reduce—but not eliminate—HCM prevalence in affected breeds, since many cases arise from unknown mutations [2]

Echocardiographic Breeding Screening

• ·Regular echocardiographic screening of breeding cats (annually or every 1–2 years) in predisposed breeds is recommended by cardiologists, as genetic testing alone is insufficient to detect all HCM cases [1][2]
• ·Cats with confirmed HCM on echocardiography should ideally be removed from breeding programs

Control of Secondary Causes

• ·Routine monitoring of blood pressure and thyroid function in middle-aged to senior cats (>6 years) enables early detection and treatment of hypertension and hyperthyroidism, thereby preventing secondary (non-primary) LVH that may be mistaken for or compound HCM [1][2]

Monitoring of At-Risk and Affected Cats

• ·Regular veterinary cardiac examinations (including auscultation) and periodic echocardiography for cats in high-risk breeds or with a family history of HCM allow early detection and intervention [1][2]
• ·Owner education about home resting respiratory rate monitoring can facilitate early identification of subclinical-to-clinical disease progression [1]

No Vaccine Available

• ·HCM is not an infectious disease; no vaccine exists or is applicable [1][2]

METADATA